Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun 3;384(22):2161-2163.
doi: 10.1056/NEJMc2104192. Epub 2021 Apr 7.

Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351)

Thandeka Moyo-Gwete  1 , Mashudu Madzivhandila  1 , Zanele Makhado  1 , Frances Ayres  1 , Donald Mhlanga  1 , Brent Oosthuysen  1 , Bronwen E Lambson  1 , Prudence Kgagudi  1 , Houriiyah Tegally  2 , Arash Iranzadeh  3 , Deelan Doolabh  3 , Lynn Tyers  3 , Lionel R Chinhoyi  3 , Mathilda Mennen  3 , Sango Skelem  3 , Gert Marais  3 , Constantinos K Wibmer  1 , Jinal N Bhiman  1 , Veronica Ueckermann  4 , Theresa Rossouw  5 , Michael Boswell  4 , Tulio de Oliveira  2 , Carolyn Williamson  3 , Wendy A Burgers  3 , Ntobeko Ntusi  3 , Lynn Morris  6 , Penny L Moore  6
Affiliations

Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351)

Thandeka Moyo-Gwete et al. N Engl J Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1. Cross-Reactivity of Neutralizing Antibody Responses.
Plasma samples from patients infected with the original variant (D614G) (Panel A) and from patients in the Groote Schuur Hospital (GSH) cohort who were infected with the 501Y.V2 variant (Panels B, C, and D) were compared for their neutralization cross-reactivity against other variants. One analysis (Panel C) was limited to samples from the 22 patients who had positive titers of binding antibodies and in whom sequencing had confirmed infection with 501Y.V2. A subset of 10 samples (Panel D) was assayed against 501Y.V3 pseudoviruses. Neutralizing antibody responses elicited by 501Y.V2 infection were more cross-reactive than those elicited by infection with the original variant. Plasma from patients infected with the original variant elicited titers against 501Y.V2 that were, on average, approximately one ninth of the titer elicited against the original variant (Panel A). In contrast, plasma from patients who had been infected with 501Y.V2 elicited responses against the original variant that were one third (Panel B) and one fourth (Panel C) of those elicited against the 501Y.V2 variant. Plasma from some of the patients infected with 501Y.V2 elicited even greater responses against 501Y.V3 than against 501Y.V2 (approximately three times as high) (Panel D). In each graph, the orange line indicates the slope between the median neutralization potencies of the samples tested. In the pie charts, blue indicates the percentage of samples with neutralization activity and red the percentage of samples with no detectable neutralization activity. The threshold of detection for the neutralization assay is a 50% inhibitory dilution (ID50) of 20. All experiments were performed in duplicate, and the mean values are shown. Data for the original variant plasma are from Wibmer et al.
See this image and copyright information in PMC

Update of

References

    1. Tegally H, Wilkinson E, Giovanetti M, et al. Emergence of a SARS-CoV-2 variant of concern with mutations in spike glycoprotein. Nature 2021. March 9 (Epub ahead of print). - PubMed
    1. Wibmer CK, Ayres F, Hermanus T, et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nat Med 2021. March 2 (Epub ahead of print). - PubMed
    1. Wang P, Nair MS, Liu L, et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. February 12, 2021. (https://www.biorxiv.org/content/10.1101/2021.01.25.428137v3). preprint. - PubMed
    1. Cele S, Gazy I, Jackson L, et al. Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma. Nature 2021. March 29 (Epub ahead of print). - PMC - PubMed
    1. Fontanet A, Autran B, Lina B, Kieny MP, Karim SSA, Sridhar D. SARS-CoV-2 variants and ending the COVID-19 pandemic. Lancet 2021;397:952-954. - PMC - PubMed